ATP Citrate Lyase (ACL) Inhibitor
Bempedoic acid1 is an oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver and thereby lowers circulating low-density lipoprotein cholesterol (LDL-C) levels2. Bempedoic acid and the fixed combination of bempedoic acid with ezetimibe are intended for patients who need additional LDL-C lowering in spite of maximally tolerated statin therapy.
1 Bempedoic Acid is an investigational agent and has not been approved by the EMA or any other regulatory agency worldwide as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.
2 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance, JAHA 2019.